Does Medica Cover GLP-1 for Weight Loss? Commercial, Medicare, and Medicaid

In most cases, Medica does not cover GLP-1 medications for weight loss. Since January 1, 2024, fully insured commercial plans exclude Wegovy, Saxenda, and other appetite suppressants when prescribed for weight management.1Medica. Commercial Product and Benefit Changes for 2024 Whether you can get a GLP-1 covered through Medica depends on the kind of plan you have, what the prescription is treating, and in some cases what your employer has chosen to include.

Fully Insured Commercial Plans

If you get coverage through a fully insured Medica group plan, GLP-1 drugs prescribed for weight loss are excluded. As groups renewed through 2024, Medica removed Wegovy, Saxenda, phentermine, and other anorexiants from the covered drug list when the indication is weight management.1Medica. Commercial Product and Benefit Changes for 2024 BMI, comorbidities, and provider recommendations do not change that result on these plans.

Medica’s 2025 commercial drug list reinforces this. The formulary notes that listing a weight-loss drug “does not imply coverage” and directs members to their benefit plan documents.2Medica. 2025 Commercial Drug List For most fully insured members, that document confirms the exclusion.

Self-Funded Employer Plans

Self-funded plans work differently. If your employer self-funds its health benefits and uses Medica only to administer them, the 2024 weight-loss drug exclusion is optional, and each employer decides on its own whether to cover GLP-1s for weight loss.1Medica. Commercial Product and Benefit Changes for 2024

The only reliable way to find out is to check your Summary Plan Description or call the member services number on your Medica card. Some self-funded employers run GLP-1 coverage as a separate carve-out benefit paired with behavioral coaching and dose management rather than through the standard pharmacy benefit.

Individual and Family Plans

Medica sells individual and family business (IFB) plans in Minnesota and Iowa, each with its own formulary. The 2024 announcement did not call out IFB plans as a separate category, and coverage decisions for weight-loss drugs on these plans sit with the state-specific drug list.1Medica. Commercial Product and Benefit Changes for 2024 Members should pull the current IFB formulary for their state or call Medica directly before assuming a GLP-1 will be covered; prior authorization is likely either way.3Medica. Individual and Family Pharmacy Information

When Medica Does Cover GLP-1 Drugs

Medica continues to cover several GLP-1 medications when they are prescribed for type 2 diabetes. Ozempic, Rybelsus, Trulicity, Byetta, Mounjaro, Victoza, and Bydureon all remain on the formulary for that indication.1Medica. Commercial Product and Benefit Changes for 2024 Each requires prior authorization and a diabetes diagnosis. A prescription for Ozempic or Mounjaro written off-label for weight loss on a fully insured plan will be denied.

Medicare Members and the GLP-1 Bridge Program

Medica’s Medicare Advantage and Part D plans do not cover GLP-1 drugs for weight loss. Zepbound, for example, is not on the 2025 Medicare formulary.4Medica. 2025 Medicare Drug Formulary That reflects the longstanding Medicare Part D exclusion of weight-loss medications.

A federal demonstration opens a separate path starting July 1, 2026. The Medicare GLP-1 Bridge program runs outside Part D, so Medica does not administer the claims. Eligible Medicare beneficiaries can get Wegovy (injection or tablet), Zepbound (KwikPen only), or Foundayo (tablet) for a $50 monthly copay, with Humana processing prior authorizations and pharmacy payments.5Medicare.gov. Weight Loss Drugs6CMS. Medicare GLP-1 Bridge

To qualify, you must be 18 or older, have Medicare drug coverage, and meet one of these clinical thresholds:

  • BMI of 35 or higher, no additional condition required.
  • BMI of 30 to 34.99 with at least one qualifying condition, such as diastolic heart failure, uncontrolled hypertension, chronic kidney disease stage 3a or higher, prediabetes, prior heart attack or stroke, or symptomatic peripheral artery disease.
  • BMI of 27 to 29.99 with prediabetes, prior heart attack or stroke, or symptomatic peripheral artery disease.

If you already get a GLP-1 through Part D for diabetes, moderate-to-severe sleep apnea, or fatty liver disease, you are not eligible for the Bridge program and should keep filling through your Part D plan.5Medicare.gov. Weight Loss Drugs The $50 copay does not apply toward a Part D deductible or out-of-pocket limit and cannot be reduced by Extra Help or the Medicare Prescription Payment Plan.6CMS. Medicare GLP-1 Bridge

The Bridge program is scheduled to run through December 31, 2027, and is designed to lead into the BALANCE Model, a longer-term Part D initiative starting January 1, 2027. Continuing access past the Bridge window will require enrolling in a Part D plan that opts into BALANCE.6CMS. Medicare GLP-1 Bridge

Minnesota Medicaid (MHCP)

If your coverage comes through Minnesota Health Care Programs, GLP-1 drugs like Wegovy and Saxenda are covered for weight loss, subject to prior authorization. Approval requires meeting BMI thresholds and documenting diet and physical activity. For renewal, adults must show at least 5% weight loss during the initial approval period.7Minnesota Department of Human Services. Anti-Obesity Medications Prior Authorization Criteria Legislation introduced in March 2026 would have removed this coverage but drew organized opposition from advocacy groups.8Obesity Action Coalition. Protecting GLP-1 Access in Minnesota

If Medica Denies Your Claim

Members and providers can appeal a denial by submitting a Medica Adjustment/Appeal Request Form with clinical documentation that supports medical necessity, not just lab results.9Medica. Appeal, Adjustment, and Record Submission Training Appeals generally must be filed within 12 months of the claim processing date, and your Explanation of Benefits may list a member-specific deadline that differs from the provider timeline.

Watch one trap. Since January 1, 2025, if a service required prior authorization and none was obtained before the claim was filed, the claim is denied with no appeal available. Providers have a 10-business-day window after the service to submit a retroactive authorization before filing.9Medica. Appeal, Adjustment, and Record Submission Training For a GLP-1 that does fall within a covered indication like diabetes, make sure the prior authorization is on file first.

Pending Minnesota Legislation

Minnesota lawmakers have introduced House File 690 and Senate File 1053, which would require state-regulated insurers to cover obesity treatment, including FDA-approved weight-loss drugs, bariatric surgery, and behavioral interventions.10Axios. Minnesota Insurance Mandate Weight Loss Drugs11Minnesota Office of the Revisor of Statutes. HF 69012Minnesota Office of the Revisor of Statutes. SF 1053 If passed, the mandate would reach fully insured Minnesota plans but not self-funded employer plans. Until something passes, assume current Medica policy applies.